21190975|clinical|C1611832^C1555900^C1608518^C3272565^C0205210|start=0|end=8|CONC
21190975|risk factors|C1553898^C0035648|start=9|end=21|CONC
21190975|malignancy|C0006826^C1306459|start=26|end=36|DISO
21190975|survival|C0038952^C0220921|start=49|end=57|ACTI^CONC
21190975|pheochromocytomas|C0031511|start=75|end=92|DISO
21190975|paragangliomas|C0030421|start=109|end=123|DISO
21190975|primary tumor size|C1302656|start=125|end=143|PHYS
21190975|primary tumor|C0677930|start=148|end=161|DISO
21190975|location|C1550511^C1515974^C1555588^C0450429|start=162|end=170|CONC^ANAT
21190975|prognostic|C0220901|start=174|end=184|CONC
21190975|context|C0542559|start=197|end=204|CONC
21190975|pheochromocytomas|C0031511|start=206|end=223|DISO
21190975|paragangliomas|C0030421|start=240|end=254|DISO
21190975|rare|C0522498^C1514917^C0521114|start=259|end=263|GENE^CONC
21190975|neuroendocrine tumors|C0206754|start=264|end=285|DISO
21190975|histological|C0205462|start=307|end=319|CONC
21190975|molecular markers|C0005516|start=323|end=340|PHYS
21190975|identified|C1551388^C0205396|start=351|end=361|CONC
21190975|differentiate|C0205615|start=365|end=378|CONC
21190975|benign|C0205183|start=379|end=385|CONC
21190975|malignant tumors|C0006826|start=391|end=407|DISO
21190975|objective|C0018017^C1571702^C2979883|start=409|end=418|PHYS^CONC
21190975|aim|C0279214^C1947946^C3540471^C1413231^C3540472|start=424|end=427|PROC^GENE^CONC
21190975|primary tumor|C0677930|start=453|end=466|DISO
21190975|location|C1550511^C1515974^C1555588^C0450429|start=467|end=475|CONC^ANAT
21190975|size|C0456389^C1552077^C1879945|start=480|end=484|CONC
21190975|associated with|C0332281|start=489|end=504|CONC
21190975|malignancy|C0006826^C1306459|start=505|end=515|DISO
21190975|decreased|C0392756^C0205216^C0442797|start=520|end=529|CONC
21190975|survival|C0038952^C0220921|start=530|end=538|ACTI^CONC
21190975|design|C2983265^C1707689|start=540|end=546|ACTI^CONC
21190975|setting|C0542559|start=551|end=558|CONC
21190975|performed|C0884358|start=563|end=572|CONC
21190975|retrospective|C0035363^C1514923|start=575|end=588|PROC^CONC
21190975|chart review|C0541653|start=589|end=601|PROC
21190975|pheochromocytoma|C0031511^C2697417|start=626|end=642|DISO^GENE
21190975|sympathetic paraganglioma|C0334415|start=646|end=671|DISO
21190975|study|C0947630^C2603343^C0557651^C0008972^C1705923^C1880229|start=687|end=692|PROC^OBJC^CONC
21190975|group|C1552516^C1561557^C1705428^C0441833|start=693|end=698|ORGA^CONC
21190975|main|C0205225^C1542147|start=723|end=727|CONC
21190975|outcome measures|C0086749|start=728|end=744|CONC
21190975|survival|C0038952^C0220921|start=754|end=762|ACTI^CONC
21190975|disease|C0012634|start=767|end=774|DISO
21190975|specific|C0205369^C1552740|start=775|end=783|CONC
21190975|survival|C0038952^C0220921|start=784|end=792|ACTI^CONC
21190975|analyzed|C0936012|start=798|end=806|PROC
21190975|tumor size|C0475440|start=820|end=830|CONC
21190975|location|C1550511^C1515974^C1555588^C0450429|start=835|end=843|CONC^ANAT
21190975|percent|C0439165|start=860|end=867|CONC
21190975|paragangliomas|C0030421|start=897|end=911|DISO
21190975|pheochromocytomas|C0031511|start=937|end=954|DISO
21190975|metastatic disease|C2939420^C0027627|start=959|end=977|DISO
21190975|metastasis|C2939420^C0027627|start=979|end=989|DISO
21190975|associated with|C0332281|start=1008|end=1023|CONC
21190975|primary tumors|C0677930|start=1024|end=1038|DISO
21190975|located in|C0332285|start=1039|end=1049|CONC
21190975|mediastinum|C0025066^C0496915^C1278909|start=1054|end=1065|DISO^ANAT
21190975|paraaortic|C0456269|start=1099|end=1109|ANAT
21190975|area|C0205146^C0017446^C1510751|start=1110|end=1114|GEOG^ACTI^CONC
21190975|including|C0332257|start=1116|end=1125|CONC
21190975|organ of zuckerkandl|C0030378|start=1130|end=1150|ANAT
21190975|primary tumor|C0677930|start=1162|end=1175|DISO
21190975|larger|C1704243^C0549177|start=1180|end=1186|CONC
21190975|metastases|C0027627^C2939419|start=1204|end=1214|DISO
21190975|metastatic disease|C2939420^C0027627|start=1240|end=1258|DISO
21190975|paragangliomas|C0030421|start=1299|end=1313|DISO
21190975|survival|C0038952^C0220921|start=1336|end=1344|ACTI^CONC
21190975|pheochromocytomas|C0031511|start=1364|end=1381|DISO
21190975|increased|C0442805^C0205217|start=1396|end=1405|CONC
21190975|tumor size|C0475440|start=1406|end=1416|CONC
21190975|associated with|C0332281|start=1421|end=1436|CONC
21190975|survival|C0038952^C0220921|start=1453|end=1461|ACTI^CONC
21190975|paragangliomas|C0030421|start=1501|end=1515|DISO
21190975|twice|C1720725^C1948050|start=1521|end=1526|CONC
21190975|disease|C0012634|start=1547|end=1554|DISO
21190975|pheochromocytomas|C0031511|start=1574|end=1591|DISO
21190975|hazard ratio|C2985465|start=1593|end=1605|CONC
21190975|confidence interval|C0009667|start=1618|end=1637|CONC
21190975|multivariate analysis|C0026777|start=1670|end=1691|CONC
21190975|location|C1550511^C1515974^C1555588^C0450429|start=1697|end=1705|CONC^ANAT
21190975|primary tumor|C0677930|start=1713|end=1726|DISO
21190975|was a|C1278569|start=1727|end=1732|CONC
21190975|predictor|C2698872|start=1742|end=1751|CONC
21190975|metastases|C0027627^C2939419|start=1755|end=1765|DISO
21190975|size|C0456389^C1552077^C1879945|start=1779|end=1783|CONC
21190975|primary tumor|C0677930|start=1791|end=1804|DISO
21190975|conclusions|C1707478|start=1806|end=1817|CONC
21190975|size|C0456389^C1552077^C1879945|start=1823|end=1827|CONC
21190975|location|C1550511^C1515974^C1555588^C0450429|start=1832|end=1840|CONC^ANAT
21190975|primary tumor|C0677930|start=1848|end=1861|DISO
21190975|significant|C0750502^C1546944^C0237881|start=1867|end=1878|CONC
21190975|clinical|C1611832^C1555900^C1608518^C3272565^C0205210|start=1879|end=1887|CONC
21190975|risk factors|C1553898^C0035648|start=1888|end=1900|CONC
21190975|metastasis|C2939420^C0027627|start=1905|end=1915|DISO
21190975|decreased|C0392756^C0205216^C0442797|start=1920|end=1929|CONC
21190975|survival|C0038952^C0220921|start=1938|end=1946|ACTI^CONC
21190975|duration|C0449238|start=1947|end=1955|CONC
21190975|findings|C2607943^C2926606^C3539655|start=1963|end=1971|PHYS^CONC
21190975|follow-up|C1704685^C1522577^C3274571|start=1986|end=1995|PROC^CONC
21190975|treatment|C1705169^C0039798^C1533734^C3161471^C1522326^C3538994^C0087111|start=2000|end=2009|PROC^CONC
21190975|tumors|C0027651|start=2020|end=2026|DISO
